Products & safety
Altitude sickness: acclimatization, illness types and descent
On this page
Altitude sickness can follow a rapid move to higher elevation. Headache with nausea, dizziness or fatigue may represent acute mountain sickness; confusion or breathlessness at rest can signal an emergency. Similar symptoms have other causes, so familiarity with a mountain route cannot establish a diagnosis.[1]
Terms and practical distinctions
| Term | Meaning | Boundary |
|---|---|---|
| Acute mountain sickness, AMS | Symptoms after ascent, commonly headache with other illness symptoms | Do not continue ascending while symptomatic[2] |
| High-altitude cerebral edema, HACE | Brain swelling, with confusion or loss of coordination | Requires immediate descent and emergency help[7][3] |
| High-altitude pulmonary edema, HAPE | Fluid buildup in the lungs, with breathing difficulty | Can occur with or without AMS[6][3] |
The oxygen percentage and oxygen availability differ
TravelHealthPro explains that air still contains about twenty-one percent oxygen at altitude. Falling barometric (air) pressure means fewer oxygen molecules are available in each breath. Acclimatization is the body’s adjustment to that exposure; it takes time rather than a moment of determination. The usual discussion begins around 2,500 meters, but susceptibility varies and illness can occur lower. Medical conditions, the planned route and access to evacuation belong in advance planning. Limited evidence in children and difficulty recognizing symptoms in preverbal children add uncertainty.[7]
Sleeping elevation matters as well as the highest viewpoint
CDC distinguishes a daytime visit to higher ground from sleeping there. Gradual ascent and returning lower to sleep after a higher excursion can allow acclimatization. People with relevant heart or lung disease should discuss travel beforehand. If symptoms develop, do not ascend further until they resolve. Worsening symptoms despite rest require descent. Severe brain or lung illness requires immediate movement to lower elevation, with assistance and emergency treatment. A medication discussion before departure does not replace these decisions during the trip.[2]
Evidence & uncertainty
Preventive drug trials mostly measured uncomplicated acute mountain sickness. Evidence that fewer participants developed that outcome does not establish protection against every severe altitude complication. Older prevention and treatment reviews also cover different interventions and follow-up periods.[4]
Selected-source overview · Independent review pendingPublished questions
Does higher altitude mean air has a smaller percentage of oxygen?
Selected-source overview · Independent review pending. Read the evidence context.
No. The fraction remains about twenty-one percent, but lower pressure makes fewer oxygen molecules available per breath. Oxygen fraction and availability are different quantities.[7]
Evidence behind this answer
- Altitude illness
official guidance · Date not stated
Selected relevant original official page passages inspected · Pressure and oxygen fraction; acclimatization; children and travel planning
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does visiting a high viewpoint expose someone in the same way as sleeping there?
Selected-source overview · Independent review pending. Read the evidence context.
No. CDC distinguishes daytime exposure from sleeping elevation. The ascent schedule and overnight height both matter for acclimatization.[2]
Evidence behind this answer
- Travel to High Altitudes
official guidance · Date not stated
Selected relevant original official page passages inspected · Sleeping altitude, staged ascent, symptom response and immediate descent
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does preventing mild mountain sickness prove protection from HACE and HAPE?
Selected-source overview · Independent review pending. Read the evidence context.
No. The selected prevention review had little evidence on those severe outcomes. Fewer AMS episodes cannot be treated as proof of complete protection.[4]
Evidence behind this answer
- Interventions for preventing high altitude illness: commonly-used classes of drugs
systematic review · 2017
Original review summary and abstract inspected; underlying full trials not independently appraised · 2017 review summary; sixteen acetazolamide trials; AMS risk ratio and harms
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do short altitude-treatment trials establish long-term recovery?
Selected-source overview · Independent review pending. Read the evidence context.
No. Follow-up was usually less than one day and studies were small. Their measured symptom outcomes do not establish long-term recovery or survival.[5]
Evidence behind this answer
- Interventions for treating acute high altitude illness
systematic review · 2018
Original review summary and abstract inspected; underlying full trials not independently appraised · 2018 review; thirteen studies, follow-up and reporting limitations
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is 2,500 meters a sharp boundary below which altitude illness is impossible?
Selected-source overview · Independent review pending. Read the evidence context.
No. The WMS guideline explains that susceptible people can develop altitude illness lower. Elevation thresholds guide planning rather than guaranteeing safety.[3]
Evidence behind this answer
- Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update
professional clinical guideline · 2024
Selected original full-text definitions, methods and clinical context inspected; no independent full-guideline appraisal · Definitions, threshold variability, differential diagnosis and methods
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Should confusion or breathlessness at rest at altitude wait until tomorrow?
Selected-source overview · Independent review pending. Read the evidence context.
No. NHS treats those as severe warning signs requiring immediate medical help and descent if possible, rather than waiting for ordinary symptoms to improve.[1]
Evidence behind this answer
- Altitude sickness
official guidance · Date not stated
Selected relevant original official page passages inspected · Symptoms; stop ascent; descent; severe warning signs
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Acetazolamide trials concern a defined prevention outcome
The 2017 Cochrane prevention review included sixty-four studies of several drugs. For acetazolamide versus placebo, sixteen studies with 2,301 participants found less acute mountain sickness: risk ratio 0.47, with a ninety-five percent confidence interval from 0.39 to 0.56. Most studies concerned uncomplicated illness, with little information on HACE or HAPE. Participants were mainly adults, and settings included mountains and altitude chambers. Tingling was more common, while other adverse events were incompletely reported. This is not a personal prescription or a guarantee.[4]
Small treatment studies cannot settle emergency care
The 2018 Cochrane treatment review searched through August 2017 and included thirteen studies with 468 participants. Most concerned mild or moderate acute mountain sickness, and follow-up was usually under a day. Small samples and incomplete reporting limited conclusions about symptom effects and harms; mortality was not reported as an outcome. These comparisons do not establish that waiting at altitude is safe for severe illness. The absence of a convincing trial result for one treatment is different from evidence that a dangerous condition needs no action.[5]
Clinical categories have boundaries and competing explanations
The 2024 Wilderness Medical Society update reviews prevention and treatment of AMS, HACE and HAPE. It notes that thresholds are not absolute and symptoms are nonspecific. An altitude-related headache may have another explanation; severe lung illness can also require distinguishing other causes of breathlessness. The guideline synthesizes trials, observational studies and clinical experience rather than supplying a home diagnostic test. Its own recommendation grades belong to that guideline. This selected-source explanation has not repeated its grading or independently appraised every included study.[3]
Severe symptoms change the response immediately
NHS guidance identifies confusion, poor coordination, hallucinations, breathlessness at rest, frothy cough, blue or grey lips, and difficulty waking as severe warning signs. Get medical help immediately and move to lower altitude if possible. For ordinary symptoms, stop ascent and tell a companion; seek descent if symptoms worsen or do not improve. A person with severe signs must not wait a day to see whether rest helps. UK service advice should be translated into the local emergency and mountain-rescue arrangements before travel.[1]
References
- Altitude sickness
Official guidance
NHS · Content/publication date: not stated
Accessed: 2026-10-14 UTC · Selected relevant original official page passages inspected
Cited sections: Symptoms; stop ascent; descent; severe warning signs - Travel to High Altitudes
Official guidance
CDC · Content/publication date: not stated
Accessed: 2026-10-14 UTC · Selected relevant original official page passages inspected
Cited sections: Sleeping altitude, staged ascent, symptom response and immediate descent - Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update
Professional clinical guideline
Luks AM and colleagues / WMS · Content/publication date: 2024
Accessed: 2026-10-14 UTC · Selected original full-text definitions, methods and clinical context inspected; no independent full-guideline appraisal
Cited sections: Definitions, threshold variability, differential diagnosis and methods2024 issue; first published online December 27, 2023.
- Interventions for preventing high altitude illness: commonly-used classes of drugs
Systematic review
Nieto Estrada VH and colleagues / Cochrane · Content/publication date: 2017
Accessed: 2026-10-14 UTC · Original review summary and abstract inspected; underlying full trials not independently appraised
Cited sections: 2017 review summary; sixteen acetazolamide trials; AMS risk ratio and harms - Interventions for treating acute high altitude illness
Systematic review
Simancas-Racines D and colleagues / Cochrane · Content/publication date: 2018
Accessed: 2026-10-14 UTC · Original review summary and abstract inspected; underlying full trials not independently appraised
Cited sections: 2018 review; thirteen studies, follow-up and reporting limitations - Pulmonary edema
Official guidance
MedlinePlus / A.D.A.M. · Content/publication date: not stated
Accessed: 2026-10-14 UTC · Selected relevant original official page passages inspected
Cited sections: Definition: abnormal fluid buildup in lungs causing breathlessness; high altitude among causes - Altitude illness
Official guidance
NaTHNaC / TravelHealthPro · Content/publication date: not stated
Accessed: 2026-10-14 UTC · Selected relevant original official page passages inspected
Cited sections: Pressure and oxygen fraction; acclimatization; children and travel planning
Scope & review
- Population
- General readers; age, exposure and study populations distinguished
- Exposure or intervention
- Altitude sickness: acclimatization, illness types and descent
- Comparison
- Gradual versus rapid ascent; preventive acetazolamide versus placebo; mild symptoms versus severe brain or lung illness
- Outcomes
- Source-specific illness, injuries, skills, preventive behavior and harms
- Timeframe
- Immediate exposure and source-specific study follow-up
- Jurisdiction
- US CDC, UK NHS/NaTHNaC, international WMS guidance and dated Cochrane reviews; emergency services depend on destination.
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-14 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.
What this article still leaves open
- How should a particular route, health condition and evacuation access affect planning?
- Severe-outcome and child evidence remains limited; qualified review is pending.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.